New York, February 03, 2014 -- Moody's Investors Service said that BioScrip, Inc.'s ("BioScrip") credit agreement amendment to its existing term loan and pending sale of the company's Home Health business are credit positive, but do not impact the B3 Corporate Family Rating or the stable outlook. For further information, please see www.moodys.com.
Vollständigen Artikel bei Moodys lesen